Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications
- Author
- FERRARA, Napoleone1
[1] Genentech, Inc., South San Francisco, CA, United States - Conference title
- Blocking tumor angiogenesis: the role of bevacizumab (Avastin)
- Conference name
- Symposium Blocking Tumor Angiogenesis: The Role of Avastin (Sonoma, CA 2001-05)
- Author (monograph)
- JAIN, Rakesh K (Editor)1
[1] Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, MA, United States - Source
Seminars in oncology. 2002, Vol 29, Num 6, pp 10-14, 5 p ; SUP16 ; ref : 34 ref
- CODEN
- SOLGAV
- ISSN
- 0093-7754
- Scientific domain
- Medical oncology
- Publisher
- Elsevier, Philadelphia, PA
- Publication country
- United States
- Document type
- Conference Paper
- Language
- English
- Keyword (fr)
- Angiogenèse Antiangiogénique Anticancéreux Anticorps monoclonal Bévacizumab Dégénérescence Essai clinique phase III Facteur angiogène Facteur croissance endothélium vasculaire Homme Immunomodulateur Immunothérapie Macula Néovascularisation Traitement Tumeur maligne Cytokine Facteur croissance Maculopathie Oeil pathologie Rétinopathie
- Keyword (en)
- Angiogenesis Antiangiogenic agent Antineoplastic agent Monoclonal antibody Bevacizumab Degeneration Phase III trial Angiogenic factor Vascular endothelium growth factor Human Immunomodulator Immunotherapy Macula Neovascularization Treatment Malignant tumor Cytokine Growth factor Maculopathy Eye disease Retinopathy
- Keyword (es)
- Angiogénesis Antiangiogenico Anticanceroso Anticuerpo monoclonal Bevacizumab Degeneración Ensayo clínico fase III Factor angiógeno Factor crecimiento endotelio vascular Hombre Inmunomodulador Inmunoterapia Mácula Neovascularización Tratamiento Tumor maligno Citoquina Factor crecimiento Maculopatía Ojo patología Retinopatía
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02Q Immunomodulators
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R03 Immunotherapy
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 14471041
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/S0093-7754(02)70064-X 
https://dx.doi.org/10.1016/S0093-7754(02)70064-X
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0093-7754(02)70064-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:111:\"Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Seminars in oncology\";s:9:\"\u0000*\u0000stitle\";s:12:\"Semin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:2:\"10\";s:8:\"\u0000*\u0000epage\";s:2:\"14\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0093-7754\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"FERRARA\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Napoleone\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"SOLGAV\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:5:\"SUP16\";s:9:\"\u0000*\u0000btitle\";s:62:\"Blocking tumor angiogenesis: the role of bevacizumab (Avastin)\";s:8:\"\u0000*\u0000title\";s:111:\"Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0093-7754(02)70064-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:111:\"Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Seminars in oncology\";s:9:\"\u0000*\u0000stitle\";s:12:\"Semin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:2:\"10\";s:8:\"\u0000*\u0000epage\";s:2:\"14\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0093-7754\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"FERRARA\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Napoleone\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"SOLGAV\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:5:\"SUP16\";s:9:\"\u0000*\u0000btitle\";s:62:\"Blocking tumor angiogenesis: the role of bevacizumab (Avastin)\";s:8:\"\u0000*\u0000title\";s:111:\"Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0093-7754(02)70064-X\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0093-7754(02)70064-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:111:\"Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Seminars in oncology\";s:9:\"\u0000*\u0000stitle\";s:12:\"Semin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:2:\"10\";s:8:\"\u0000*\u0000epage\";s:2:\"14\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0093-7754\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"FERRARA\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Napoleone\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"SOLGAV\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:5:\"SUP16\";s:9:\"\u0000*\u0000btitle\";s:62:\"Blocking tumor angiogenesis: the role of bevacizumab (Avastin)\";s:8:\"\u0000*\u0000title\";s:111:\"Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0093-7754(02)70064-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:111:\"Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Seminars in oncology\";s:9:\"\u0000*\u0000stitle\";s:12:\"Semin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:2:\"10\";s:8:\"\u0000*\u0000epage\";s:2:\"14\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0093-7754\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"FERRARA\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Napoleone\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"SOLGAV\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:5:\"SUP16\";s:9:\"\u0000*\u0000btitle\";s:62:\"Blocking tumor angiogenesis: the role of bevacizumab (Avastin)\";s:8:\"\u0000*\u0000title\";s:111:\"Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0093-7754(02)70064-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:111:\"Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Seminars in oncology\";s:9:\"\u0000*\u0000stitle\";s:12:\"Semin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:2:\"10\";s:8:\"\u0000*\u0000epage\";s:2:\"14\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0093-7754\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"FERRARA\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Napoleone\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"SOLGAV\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:5:\"SUP16\";s:9:\"\u0000*\u0000btitle\";s:62:\"Blocking tumor angiogenesis: the role of bevacizumab (Avastin)\";s:8:\"\u0000*\u0000title\";s:111:\"Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
